<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02512133</url>
  </required_header>
  <id_info>
    <org_study_id>1</org_study_id>
    <nct_id>NCT02512133</nct_id>
  </id_info>
  <brief_title>MIGS VS SLT Comparison in Glaucoma Patients</brief_title>
  <official_title>MIGS VS SLT in Glaucoma Patients: Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Siena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Turin, Italy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the intraocular pressure (IOP) and number of glaucoma medications lowering of
      microinvasive glaucoma surgery (MIGS) with the implantation of the trabecular device Hydrus
      (Ivantis) as a solo procedure and 360° selective laser trabeculoplasty (SLT) to treat primary
      open angle glaucoma (POAG).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible study patients diagnosed with POAG and not sufficiently controlled by, intolerant
      of, or non-compliant with their current IOP-lowering regimen. Patients with IOP&gt;21 mm Hg upon
      at least two consecutive measurements. Study subjects with typical glaucomatous visual field
      (VF) loss on Octopus or Humphrey automated perimetry (Carl Zeiss Meditec, Dublin, CA) and
      glaucomatous alterations to the optic nerve head. Visual field classified as glaucomatous
      according to the European Glaucoma Society guidelines.

      Exclusion criteria : eye surgery in the previous 6 months, any previous surgery for glaucoma,
      evidence of glaucoma of a type other than POAG, and medication with systemic or topical
      steroids.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in the intraocular pressure compared to baseline</measure>
    <time_frame>up to 12 months</time_frame>
    <description>measurement with GAT in mm Hg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in the number of glaucoma medications compared to baseline</measure>
    <time_frame>up to 12 months</time_frame>
    <description>accountability of IOP lowering medications used by the patient</description>
  </secondary_outcome>
  <other_outcome>
    <measure>change of visual acuity compared to baseline</measure>
    <time_frame>6 months and 1 year post-intervention</time_frame>
    <description>ETDRS visual acuity scale</description>
  </other_outcome>
  <other_outcome>
    <measure>change of visual field compared to baseline</measure>
    <time_frame>1 year post-intervention</time_frame>
    <description>MD and PSD</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>MIGS Hydrus Ivantis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>opening the anterior chamber (2mm.) injecting visco-material, injecting the Hydrus stent in the Schlemm's canal under gonioscopic control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laser Solutis SLT laser (Quantel Medical, Clermont-Ferrand, France): this frequency-doubled, Q-switched Nd:YAG laser emits light at a wavelength of 532 nm, with a pulse duration of 4 ns, a spot size of 400 µm and pulse energy ranging from 0.2 to 2 mJ</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MIGS Hydrus Ivantis</intervention_name>
    <description>implant of the micro stent in the nasal Schlemm's canal</description>
    <arm_group_label>MIGS Hydrus Ivantis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>360 degrees SLT</intervention_name>
    <description>Laser Solutis SLT laser (Quantel Medical, Clermont-Ferrand, France): this frequency-doubled, Q-switched Nd:YAG laser emits light at a wavelength of 532 nm, with a pulse duration of 4 ns, a spot size of 400 µm and pulse energy ranging from 0.2 to 2 mJ</description>
    <arm_group_label>SLT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary open angle glaucoma diagnosis, intolerant or unresponsive to therapy or not
             controlled with therapy

        Exclusion Criteria:

          -  eye surgery in the previous 6 months, any previous surgery for glaucoma, evidence of
             glaucoma of a type other than POAG, and medication with systemic or topical steroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Fea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Oculistica</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ophthalmology Institute, University of Turin</name>
      <address>
        <city>Turin</city>
        <zip>10138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2015</study_first_submitted>
  <study_first_submitted_qc>July 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>July 29, 2015</last_update_submitted>
  <last_update_submitted_qc>July 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Turin, Italy</investigator_affiliation>
    <investigator_full_name>Antonio Fea</investigator_full_name>
    <investigator_title>Aggregate Professor</investigator_title>
  </responsible_party>
  <keyword>MIGS</keyword>
  <keyword>SLT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

